Autonomix granted key U.S. patent for catheter-based platform technology

Autonomix (AMIX) Medical announced the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,257,071 titled Controlled sympathectomy and micro-ablation systems and methods. The newly issued ‘071 patent relates to, but is not necessarily limited to, advanced catheter-based systems that combine nerve mapping and radiofrequency ablation technologies, providing enhanced precision in treating nerve-related conditions. These systems allow for the identification and ablation of overactive nerves within the peripheral nervous system using a minimally invasive approach. The granted patent represents a significant step forward in Autonomix’s mission to improve patient outcomes by delivering more effective, less invasive treatments for neurological conditions such as chronic pain, hypertension and a myriad of other nerve-related disorders.